

Vesta

Predictive. Prognostic. **Personalized.**

The future of genitourinary oncology is precision treatment. **Lead the way, with confidence.**

What is Vesta?

Vesta is Valar Labs' GU-focused portfolio of AI-powered pathology tests, which can:

Predict patients' response to key anti-cancer treatments ▸ **Vesta® Bladder BCGPredict**

Quantify risks of recurrence and progression ▸ **Vesta® Bladder Risk Stratify**

How?

Novel Biomarkers

Valar Labs' research team has developed and validated multiple unique Vesta biomarker models in over 1,000 patients with Non-Muscle Invasive Bladder Cancer (NMIBC) using histology features.

Expertly Trained AI

Valar Labs' board-certified pathologists created 500,000+ annotations of tumors and their microenvironment to train our Computational Histology Artificial Intelligence (CHAI) platform, grounding the technology in biology.

Fast, H&E-Based Testing

Leveraging existing tumor specimens, first-of-its-kind AI analyzes pathology slides and returns actionable results in days for timely treatment decisions.

The Results ▸ Informed, efficient care for patients with NMIBC.

Vesta® Bladder BCGPredict

Predict your patient's response to BCG.

The standard of care for NMIBC is **not effective** in up to 40% of patients.

Understand what's best for each individual by adding personalized data to your clinical management strategy.

- By unlocking key features of the tumor and its microenvironment, our AI-powered test identifies patients at a higher risk of not responding to BCG.[1,2]
- Patients who test biomarker-present demonstrated a higher likelihood of success with an alternative therapy.[3]

Vesta Bladder BCGPredict

BIOMARKER PRESENT

This patient has the Vesta® Bladder BCGPredict Biomarker and is likely to have **worse outcomes with BCG therapy** compared to patients without this biomarker. Alternative treatment modalities may be considered based on this result [1-4]. (raw score -0.09)

Supplemental Clinical Evidence

Clinical Outcomes on BCG vs Alternative Therapy, by Vesta® Bladder BCGPredict Biomarker Status



In a recent publication, patients with the Vesta® Bladder BCGPredict Biomarker **present** demonstrated significantly higher recurrence rates when treated with BCG compared to treatment with intravesical sequential gemcitabine/docetaxel.

Patients for whom the Vesta® Bladder BCGPredict Biomarker was **absent** demonstrated no significant difference in recurrence rates when treated with BCG or intravesical sequential gemcitabine/docetaxel [1].

Adapted from Packiam et al. European Urology Oncology 2025

Vesta® Bladder Risk Stratify

Identify each patient's risk of recurrence and progression.

Whatever your clinical care strategy, deeper insights enable a more personalized plan.



Vesta® Bladder Risk Stratify measures a patient's risk of recurrence and progression based on tumor biology.

- Prognostic models stratify risks of high-grade recurrence and muscle-invasive progression better than existing guideline frameworks.[1,4]
- Individual patient risk scores and projected actual risks over time can aid in patient counseling for surveillance, monitoring, and surgical management decisions.

Vesta

Ready to get involved?

Get in touch to learn more about partnering with Valar Labs to advance precision cancer treatment.

(888) 862-0232 | support@valarlabs.com

Valar Labs

Reliable, actionable AI for precision cancer treatment.

Across a growing portfolio of oncology subtypes, Valar Labs' diagnostic tests use AI to interpret solid tumors and generate biomarkers that can predict response to therapies – so physicians and patients can make evidence-based treatment plans, from the start.



Every decision is critical. Make every decision informed.

1. Lotan Y, Krishna V, Abuzeid WM, et al. Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. *J Urol.* 2025;213(2):192-204. **2.** Lotan Y, Li R, Chang SS. AI Biomarkers Predict Poor Efficacy of BCG Rechallenge in Previously BCG-Treated Non-muscle Invasive Bladder Cancer. *J Urol.* Published online April 16, 2025. doi:10.1097/JU.0000000000004541 **3.** Packiam VT, McElree IM, Ghodoussipour S, et al. Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder Cancer. *Eur Urol Oncol.* Published online April 25, 2025. doi:10.1016/j.euo.2025.04.006 **4.** Chang SS, Launer B, Narayan V, et al. Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes. *Eur Urol.* Published online June 12, 2025. doi:10.1016/j.eururo.2025.05.035